Sanchez-Cordero S; Lopez-Gonzalez R; Hermoza R; Pujol-Gebelli J | Surgery for Obesity and Related Diseases, 2026 https://doi.org/10.1016/j.soard.2026.06.006

This systematic review pooled seven studies with 5,524 baseline patients and 3,735 patients available at five years. One-anastomosis gastric bypass was associated with a mean BMI of 30.1 kg/m², 33.2% total weight loss, and 74.2% excess weight loss at long-term follow-up. Reported remission rates were high across obesity-related disease, including type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea.

For bariatric surgeons, the paper reinforces OAGB as a serious durability procedure rather than a short-term weight-loss variant. The caution is equally practical: bile reflux, anemia, hypoalbuminemia, and heterogeneous follow-up remain the issues that determine patient selection and surveillance. The evidence still does not settle comparative positioning against Roux-en-Y gastric bypass or SADI-S, but it helps frame the conversation with patients who need more than sleeve-level effect.

Fried M; Michalsky D; Buchwald JN; Charpentier D; Schneider J; Gagner M | Surgical Endoscopy, 2026 https://doi.org/10.1007/s00464-026-12934-y

This comparative, non-randomized non-inferiority study examined magnetic versus stapled side-to-side jejuno-ileal bipartition in adults with BMI 30.0 to 39.9 and type 2 diabetes. At one year, the magnetic approach was non-inferior for BMI, HbA1c, and fasting plasma glucose, although it did not meet non-inferiority for weight. The authors reported no trocar-site infections and no severe device- or procedure-related adverse events.

The finding matters because magnetic compression anastomosis could reduce some technical friction in anatomy-sparing metabolic procedures. Surgeons should read this as early procedural evidence, not a mandate to change practice. The next questions are durability, reproducibility across centers, device workflow, and whether metabolic benefit can be maintained without trading away safety or nutritional simplicity.

Jalmood R; Alsafari W; Al-Asiry H; Almutairi M; Alzahrani A; et al. | Obesity Surgery, 2026 https://doi.org/10.1007/s11695-026-08788-x

This systematic review and meta-analysis included eight studies with 793,197 women, comparing 140,880 metabolic bariatric surgery patients with 652,317 nonsurgical controls. Surgery was associated with a lower incidence of breast cancer, with a pooled hazard ratio of 0.61 and a 95% confidence interval of 0.46 to 0.80. The reduction was reported in both premenopausal and postmenopausal populations.

This is the kind of cancer-risk evidence that belongs in serious counseling about obesity disease, but it should be handled carefully. The signal is compelling, yet observational data cannot prove causality or separate the full effects of weight loss, hormonal change, screening behavior, and selection bias. For programs, the practical message is broader than breast cancer alone: metabolic surgery may alter long-term disease risk in ways that are often underrepresented in access debates.

Halabi M; Sridhar S; Alam W; Varban OA; Genaw J; Carlin AM; Nasser H | Surgery for Obesity and Related Diseases, 2026 https://doi.org/10.1016/j.soard.2026.06.008

Using MBSAQIP data from 2021 through 2023, this analysis compared adult primary laparoscopic SADI-S with sleeve gastrectomy and Roux-en-Y gastric bypass. After 1:1 propensity matching, each matched cohort included 4,017 patients. SADI-S had more 30-day morbidity than sleeve, including higher emergency department use, readmission, reintervention, and reoperation, while overall complications were similar to RYGB at 3.7% versus 4.3%.

The study gives surgeons a more grounded way to discuss primary SADI-S during procedure selection. Compared with sleeve, the early burden is higher and should be part of consent. Compared with bypass, short-term safety appears within a familiar range in accredited-center data, which supports selective use by teams prepared for nutritional monitoring and complication management.

Johansson E; Wilding JPH; Upadhyay N | Journal of Medical Economics, 2026 https://doi.org/10.1080/13696998.2026.2646078

This US societal-perspective simulation model used head-to-head SURMOUNT-5 evidence to compare tirzepatide and semaglutide in adults with obesity or overweight without diabetes. The analysis moves the discussion beyond percentage weight loss and into longer-term cost, health outcomes, and value. That matters because payers are increasingly asking which incretin therapy provides enough benefit to justify sustained coverage.

For bariatric and obesity medicine programs, the paper is a reminder that medication choice will increasingly be shaped by value frameworks, not only efficacy curves. Surgical programs should watch these analyses because they influence employer benefits, payer policy, and the timing of referrals. They also help clarify when medication is a bridge, an alternative, or part of a combined metabolic strategy.

Mirsky J; Olubowale O; Kane RM | Obesity Pillars, 2026 https://doi.org/10.1177/15598276241274233

This single-site retrospective report describes virtual shared medical appointments for lifestyle support and GLP-1 medication management. The model addresses a problem most obesity programs now recognize: demand for high-touch medication care has outpaced the traditional one-on-one visit structure. Shared visits can combine education, monitoring, and medication adjustment while preserving clinician time.

The operational question is whether shared care improves access without diluting accountability. For MBS programs, the model may be useful for preoperative optimization, postoperative weight recurrence, or nonsurgical metabolic clinics linked to bariatric surgery. It also creates a structured pathway for patients who need medication support while surgical candidacy is assessed.

Estler B; Frohlich H; Tager T | International Journal of Cardiology, 2026 https://doi.org/10.1016/j.ijcard.2026.134560

This Markov model applied SUMMIT data to evaluate tirzepatide in patients with obesity-related heart failure with preserved ejection fraction in Germany. The analysis looked at cost-effectiveness and budget impact rather than weight loss alone. It places incretin therapy in the context of cardiometabolic disease management, where obesity treatment can affect symptoms, events, and resource use.

For bariatric clinicians, HFpEF is a reminder that obesity treatment often enters through organ-specific disease rather than BMI. Programs should expect more referrals framed around cardiovascular limitation, frailty, and perioperative optimization. Medication, surgery, and longitudinal disease management may all have a role, but the sequencing needs careful multidisciplinary judgment.

Mahmoud AK; Sheashaa H; Killian M | International Journal of Cardiology, 2026 https://doi.org/10.1016/j.ijcard.2026.134588

This retrospective, propensity-matched multicenter study examined GLP-1 receptor agonist therapy in patients with elevated lipoprotein(a) plus obesity or diabetes. The authors report better cardiovascular outcomes among treated patients, adding another risk-stratified angle to incretin therapy. Elevated Lp(a) remains difficult to treat directly in routine practice, so any associated risk reduction draws attention.

The bariatric relevance is patient selection and counseling. Many surgical candidates have residual cardiovascular risk that weight loss alone may not fully explain or eliminate. Studies like this support a broader metabolic-risk lens, where surgery, medication, lipid care, and cardiology input are integrated rather than siloed.

Lista S; Ballerio M; Lopez-Ortiz S | Pharmacology, Biochemistry, and Behavior, 2026 https://doi.org/10.1016/j.pbb.2026.174217

This review connects GLP-1 receptor agonists with reward circuitry, obesity, and substance-use disorders. The premise is biologically plausible: incretin signaling affects appetite, satiety, and brain pathways involved in reinforcement. The clinical field, however, still needs better trials before these observations become treatment algorithms.

For bariatric surgeons, the review is useful because reward biology already shows up in postoperative care. Alcohol use disorder, transfer addiction, grazing, and loss-of-control eating are not side issues. As medication research expands, integrated behavioral health and careful postoperative screening will remain central to safe metabolic care.

American Medical Association | June 2026 https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policies-improve-affordable-access-obesity

The AMA adopted policies aimed at improving affordable access to evidence-based obesity treatment, including attention to insurance barriers and drug affordability. For clinicians, the policy is less about a single therapy and more about recognizing obesity treatment as legitimate medical care. That framing matters in a coverage environment where medications, surgery, nutrition care, and behavioral treatment are still treated unevenly.

For MBS programs, AMA policy can help support local advocacy with employers, health systems, and payers. Access arguments should not divide surgery from medication. The stronger position is that patients need evidence-based options matched to disease severity, comorbidity burden, preference, and durability.

American College of Physicians / Annals of Internal Medicine | June 15, 2026 https://www.acponline.org/acp-newsroom/acp-issues-new-living-clinical-guideline-on-using-medications-to-manage-overweight-and-obesity

The American College of Physicians issued a living clinical guideline on medications for adults with overweight and obesity. The guidance identifies semaglutide and tirzepatide as preferred pharmacotherapy options when medication is used alongside lifestyle modification. The living format is important because obesity pharmacotherapy evidence and pricing are both changing quickly.

Bariatric surgeons should expect primary care and internal medicine referrals to reflect these recommendations. The guideline may increase medication starts before surgical consultation, but it can also improve recognition of obesity as a treatable chronic disease. Programs should be ready to discuss what medication can achieve, where it falls short, and when surgery offers a more durable or appropriate path.

NPR | June 14, 2026 https://www.npr.org/2026/06/14/nx-s1-5805984/glp1-telehealth-weight-loss-drugs

NPR reported that some employers and insurers are routing patients through telehealth vendors before covering GLP-1 obesity medications. The arrangement can standardize utilization management, but it also adds a new checkpoint between patient, prescriber, and treatment. For patients already navigating prior authorization and shortages, another gate can feel like access while functioning as delay.

MBS programs should watch these arrangements because they can shape referral timing and patient expectations. Patients may arrive after a failed telehealth medication pathway, or they may be steered away from local obesity specialists. Bariatric teams can counter that fragmentation by offering clear pathways for medication, surgery, and longitudinal follow-up within the same metabolic-care framework.

Yahoo Finance / Business Wire | April 7, 2026 https://finance.yahoo.com/sectors/healthcare/articles/forsight-robotics-makes-history-world-130000468.html

ForSight Robotics announced a first-in-human fully robot-assisted cataract procedure using its JASPER platform. This is not a bariatric surgery story, and the April date sits outside the usual June filter. It is included here as a Doc-requested surgical technology exception because it points to where procedural robotics may be heading: smaller anatomy, image guidance, and task-specific platforms.

For bariatric surgeons, the lesson is not that cataract robotics will translate directly to foregut or metabolic surgery. The more relevant point is that surgical robotics is diversifying beyond large multiport systems. As procedure-specific platforms mature, hospitals will face new capital, credentialing, and workflow decisions across service lines.

Eli Lilly and Company | June 7, 2026 https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-only-oral-glp-1-taken-without-food

Lilly reported ATTAIN analyses suggesting that oral orforglipron produced significant weight loss across menopausal stages, including roughly 14% loss in peri- and post-menopausal women without diabetes. The company is positioning the data as evidence that an oral GLP-1 could serve clinically distinct patient groups. Menopause is a logical target because weight trajectory, cardiometabolic risk, and patient demand often converge in midlife.

For MBS programs, oral GLP-1s could change the front door to obesity treatment if efficacy, tolerability, and coverage hold up. They may expand medication starts among patients reluctant to inject. They may also create longer preoperative medication histories before surgery, making documentation of response, discontinuation, and recurrence more important.

Eli Lilly and Company | May 28, 2026 https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-foundayo-mounjaro-and-retatrutide

Lilly previewed data across Foundayo, Mounjaro, and retatrutide for ADA 2026, signaling a broad push across oral GLP-1, established injectable therapy, and next-generation multi-agonist development. The company is not relying on a single obesity asset. It is building a portfolio that can compete on route, potency, comorbidity data, and patient segmentation.

Clinically, that means surgeons should expect more patients who have tried several agents before consultation. Some will have strong responses but poor persistence because of cost or tolerability. Others will need surgery because medication response is insufficient for disease severity. The pipeline makes integrated obesity care more important, not optional.

BioSpace | 2026 https://www.biospace.com/business/amgen-positions-maritide-as-potential-best-monthly-obesity-drug

BioSpace reported that Amgen is positioning MariTide as a monthly or less-frequent obesity injection, including a Phase 3 switch strategy for patients currently taking weekly GLP-1 therapy. The market argument is straightforward: if efficacy is competitive, less frequent dosing could matter for adherence and patient preference. It may also appeal to payers and employers looking for durable treatment patterns rather than short bursts of use.

For bariatric clinicians, persistence is already one of the practical weaknesses of medication-only obesity treatment. A less frequent option could help some patients stay treated longer, but it will not remove the need to identify inadequate responders or patients with surgical disease severity. Programs should be prepared for patients switching among agents before reaching surgical evaluation.

Pfizer | April 14, 2025 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist

Pfizer discontinued development of danuglipron after a potential drug-induced liver injury signal, while continuing other obesity programs including an oral GIP receptor antagonist candidate. The decision is a useful counterweight to the assumption that every oral incretin program will move smoothly into practice. Oral dosing is attractive, but systemic metabolic therapies still face safety, tolerability, and differentiation hurdles.

For MBS programs, pipeline setbacks matter because patient expectations are shaped by headlines long before drugs reach clinic. Surgeons should be ready to explain that promising pharmacology does not always become durable, accessible therapy. That message is especially important when patients delay definitive treatment while waiting for the next medication.